A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe, and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

Beyfortus is supplied as a 50mg/0.5mL and 100mg/mL prefilled syringe. The product is expected to be available for the upcoming 2023-2024 RSV season.

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial ...

Children's Health FDA approves new drug Beyfortus to protect babies, toddlers from RSV RSV can result in ‘large number’ of emergency department, physician visits, FDA official says ...

The Beyfortus antibody shot, manufactured by drugmakers AstraZeneca and Sanofi, was approved by the Food and Drug Administration in July as a way to prevent RSV in infants and children up to 24 ...

More hard-to-find doses of Beyfortus, the new immunization against respiratory syncytial virus (RSV) for infants, will be available in January, the White House says.

Beyfortus administration can be timed to coincide with the RSV season. Beyfortus has been approved for use in the European Union, the US, China, Japan, and many other countries around the world.

Beyfortus, the new RSV monoclonal antibody injection for children, is not a vaccine. But you might not know that from journalistic coverage.

Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. PPI and Industrial Production drop Wednesday morning — see how Matt Maley is trading the reaction ...

Beyfortus is a shot of protective antibodies that is approved for infants younger than 8 months and certain at-risk children under age 2, who are going into their first or second RSV season.